A study from the BMC Nephrology, by Illeon Cho and his team, is a specific warning of the risks post-COVID-19 vaccination. They state that physicians must be mindful of the possibility of (re)activation that may occur in IgA vasculitis after COVID-19 mRNA vaccines. It is crucial to monitor COVID-19 vaccine-vaccinated patients, specifically those suffering from autoimmune diseases.
The COVID-19 vaccination campaign is currently in full swing to fight the COVID-19 pandemic. Numerous patients suffering from medical comorbidities are getting vaccines to support the strongly-supported suggestion of the coronavirus 2019, (COVID-19) vaccine. However, the security of immunization in patients suffering from immune-mediated diseases is not confirmed.
There is no diagnostic instrument to prove the connection between the inflammatory condition glomerulonephritis (GN) and the mRNA COVID-19 vaccines. But, the consistency of the case reports could be related to the cause and can help create a hypothesis that can determine the causality. This can also assist in managing kidney disease effectively. The safety and efficacy of BNT162b2 and mRNA-1273 have been proven in clinical trials as well as real-world research. However, the safety of vaccinations for patients suffering from immune-mediated diseases is not confirmed. This study examines the identical.
In this research, researchers present the first case of biopsy-confirmed IgA vasculitis with nephritis that manifests as a nephrotic disorder following COVID-19 mRNA vaccination in a patient with an antecedent history of leukocytoclastic vasculitis.
A 76-year-old male with a history of skin leukocytoclastic vasculitis was diagnosed with anemia in both lower limbs. He then had nephrotic syndrome following taking the next dose of BNT162b2 COVID-19 mRNA. A renal and skin biopsy confirmed IgA vasculitis and the presence of nephritis. The patient’s medical experience with leukocytoclastic vasculitis as well as characteristics of chronic renal pathology indicates an acute recurrence of the existing IgA vasculitis after the COVID-19 vaccine. Following the steroid and renin-angiotensin system inhibitors, inflammation of the kidney and purpura was healed within a few months. Subnephrotic proteinuria and microscopic hematuria were present on the follow-up.
The team of Illeon Cho and colleagues found that doctors should be aware of the possibility of (re)activation in IgA vasculitis after COVID-19 mRNA vaccines. It is essential to continuously observe patients who have been COVID-19 vaccines, especially those suffering from immune-mediated diseases.